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A B S T R A C T
Cellular function depends on the maintenance of protein homeostasis (proteostasis) by regulated protein de-
gradation. Chronic dysregulation of proteostasis is associated with neurodegenerative and age-related diseases,
and drugs targeting components of the protein degradation apparatus are increasingly used in cancer therapies.
However, as chronic imbalances rather than loss of function mediate their pathogenesis, research models that
allow for the study of the complex eﬀects of drugs on tissue properties in proteostasis-associated diseases are
almost completely lacking. Here, to determine the functional eﬀects of impaired proteostatic ﬁne-tuning, we
applied a combination of materials science characterisation techniques to a cell-derived, in vitro model of bone-
like tissue formation in which we pharmacologically perturbed protein degradation. We show that low-level
inhibition of VCP/p97 and the proteasome, two major components of the degradation machinery, have re-
markably diﬀerent eﬀects on the bone-like material that human bone-marrow derived mesenchymal stromal
cells (hMSC) form in vitro. Speciﬁcally, whilst proteasome inhibition mildly enhances tissue formation, Raman
spectroscopic, atomic force microscopy-based indentation, and electron microscopy imaging reveal that VCP/
p97 inhibition induces the formation of bone-like tissue that is softer, contains less protein, appears to have more
crystalline mineral, and may involve aberrant micro- and ultra-structural tissue organisation. These observations
contrast with ﬁndings from conventional osteogenic assays that failed to identify any eﬀect on mineralisation.
Taken together, these data suggest that mild proteostatic impairment in hMSC alters the bone-like material they
form in ways that could explain some pathologies associated with VCP/p97-related diseases. They also de-
monstrate the utility of quantitative materials science approaches for tackling long-standing questions in biology
and medicine, and could form the basis for preclinical drug testing platforms to develop therapies for diseases
stemming from perturbed proteostasis or for cancer therapies targeting protein degradation. Our ﬁndings may
also have important implications for the ﬁeld of tissue engineering, as the manufacture of cell-derived bioma-
terial scaﬀolds may need to consider proteostasis to eﬀectively replicate native tissues.
1. Introduction
Accurate and stable maintenance of cellular protein homeostasis
(proteostasis) is critical for tissue integrity and has been linked to
longevity [1–4]. Perturbed proteostasis contributes to the pathogenesis
of a myriad of predominantly age-related diseases ranging from neu-
rodegenerative disorders to diabetes and cancer [5–7]. An elaborate
network of mechanisms constantly monitors and ﬁne-tunes the in-
tracellular proteome [8,9]. The controlled degradation of proteins that
are dysfunctional, damaged, or no longer needed is central to this
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process and is primarily executed by the ubiquitin-proteasome system
(UPS). The UPS recognises proteins that have been earmarked for de-
gradation by the addition of polyubiquitin chains, and degrades them in
the 26S proteasome, thereby regulating multiple cellular functions,
including stem cell fate [10–13]. Small molecule inhibitors of the
proteasome are widely used in the treatment of multiple myeloma, and
pharmacological targeting of other UPS components is a major area of
anti-cancer research [14].
The ATPase VCP/p97 plays a central role in the UPS by extracting
ubiquitinated proteins from cellular structures and delivering them to
the proteasome [15–19]. Drugs targeting VCP/p97 have therapeutic
potential as anti-cancer agents and for the treatment of epilepsy linked
to GABAA receptor mutations [20–22]. VCP/p97 mutations have been
associated with a multisystem degenerative disease that comprises Pa-
get's disease of bone, inclusion body myopathy, and fronto-temporal
dementia (IBMPFD), and with several other diseases of the nervous and
muscular system [23–28]. In short, VCP/p97 is essential for cellular
proteostasis and maintains skeletal and neurological health [29].
Although the pathogenesis of VCP/p97-related diseases remains to
be established, their associated cellular dysfunction has been linked to
defective proteostatic ﬁne-tuning [29–31]. This putative mechanism is
compatible with the notion that relatively minor but chronic or inter-
mittent imbalances in proteostasis contribute to many age-related dis-
eases [4,29]. However, perturbations in ﬁne-tuning that result in
chronic or intermittent imbalances in intracellular proteostasis are ex-
tremely challenging to replicate in in vitro and particularly in in vivo
models. Indeed, the relative diﬃculty of establishing a research model
when impairment rather than loss of function mediates complex tissue
pathologies has hampered research eﬀorts to identify the pathogenesis
of VCP/p97-related diseases. Moreover, there are currently no robust
experimental paradigms to study the functional eﬀects of intracellular
proteostasis imbalance or test potential therapeutic compounds that
modulate proteostasis. In short, a research platform that could mimic
the functional tissue eﬀects of chronic or intermittent proteostasis im-
balances could be invaluable in both exploring disease mechanisms and
screening for drug eﬀects.
The bone-like material that can be formed by osteogenic cells in
vitro constitutes a highly informative model system to study how im-
paired intracellular proteostasis might impact functional tissue prop-
erties. As mesenchymal stromal/stem cells (MSC) diﬀerentiate down
the osteogenic lineage and synthesise large amounts of extracellular
matrix (ECM), they become highly dependent on mechanisms which
control proteostasis [32–34]. This secreted proteinaceous matrix is then
progressively mineralised by poorly crystalline carbonated apatite,
producing a bone-like nano-composite structure in a highly controlled
process such that even small perturbations to the composition of either
the proteinaceous or mineral phases can signiﬁcantly impact bone
quality [35–37], providing a read-out of proteostasis imbalance. This
model is also of direct clinical relevance because the pathogenesis of
VCP/p97-related bone disease is incompletely understood; and whilst
proteasome inhibitors purportedly stimulate bone regeneration in
myeloma patients, the eﬀects of drugs targeting VCP/p97 on bone have
not been established [38–40]. Moreover, cell-derived, ECM-based ma-
terials have been proposed as promising scaﬀolds to direct SC diﬀer-
entiation in tissue engineering applications [41,42]. Therefore, insight
into how proteostasis imbalances may impact these biomaterials’
functional properties may be important for creating scaﬀolds that ap-
propriately mimic native tissues.
To understand how impaired proteostatic ﬁne-tuning functionally
aﬀected tissue, we created an in vitromodel using intermittent low-level
proteasome or VCP/p97 inhibition in human MSC (hMSC) as they dif-
ferentiated into osteoblasts and formed a cell-derived, bone-like mate-
rial (Supplementary Fig. 1). We show that low-level inhibition of VCP/
p97 and the proteasome diﬀerentially aﬀect the bone-like material that
hMSC form in vitro. Indeed, whilst proteasome inhibition subtly pro-
motes the formation of a material akin to native bone, Raman
spectroscopic, atomic force microscopy (AFM)-based indentation, and
electron microscopy imaging suggest that VCP/p97 inhibition results in
a material that is softer and less proteinaceous, but whose mineral
appears to be more crystalline and morphologically aberrant. These
observations suggest that mild VCP/p97 impairment in hMSC under-
going osteogenic diﬀerentiation may alter tissue physical properties in a
way that could explain some of the pathologies associated VCP/p97-
related diseases, including changes in bone mechanical properties [43].
Our results highlight the utility of applying materials science ap-
proaches to challenges that biological techniques cannot yet address.
They may also provide the basis for in vitro platforms that would allow
for the functional eﬀects of proteostasis imbalances to be evaluated
quantitatively in a model that could be particularly relevant for high-
throughput pre-clinical drug screening purposes. Finally, our ﬁndings
suggest that the fabrication of biomaterial scaﬀolds that utilise cell-
derived matrices may need to consider the eﬀects of proteostasis in
order to properly match scaﬀold properties to those of the native tissue.
2. Results
2.1. DBeQ and bortezomib induce a mild proteotoxic stress response in
diﬀerentiating hMSC
To develop an in vitro model of proteostasis imbalance, we ﬁrst
aimed to determine if we could mildly perturb proteostasis in hMSC
undergoing osteogenic diﬀerentiation. Genetic approaches to deplete
VCP/p97 or the proteasome are not suitable to study the eﬀects of mild
functional impairments [20,44]. Therefore, we took a pharmacological
approach and treated hMSC with either the well-characterised and
highly selective VCP/p97 inhibitor, DBeQ [45–48], or the ﬁrst-in-class
clinical proteasome inhibitor, bortezomib [49]. To deﬁne inhibitor
concentrations that would induce mild functional impairment without
overt toxic eﬀects, we initially determined IC50 values for viability. We
found that osteogenic diﬀerentiation increased the IC50 for DBeQ (as
determined by cellular metabolic activity) from 7.5 μM in un-
diﬀerentiated hMSC to 22 μM in their diﬀerentiated progeny (Fig. 1a).
For comparison, bortezomib, which eﬀectively kills multiple myeloma
cells in vitro at concentrations of 10–20 nM [47] (Supplementary Fig. 2),
did not reduce viability of diﬀerentiating hMSC at concentrations up to
1000 nM (Fig. 1a). Next, we aimed to determine the degree of proteo-
toxic stress caused by a concentration of DBeQ that did not aﬀect via-
bility (5 μM) at any stage of in vitro diﬀerentiation compared to a
clinically relevant concentration of bortezomib (20 nM) by quantifying
the expression of a panel of genes encoding proteins with key roles in
proteostasis. DBeQ and bortezomib both induced a very mild proteo-
toxic stress response, as determined by low-level changes in proteostasis
gene mRNA levels that were largely non-signiﬁcant (Fig. 1b and
Supplementary Table 1). For comparison, the protein glycosylation
inhibitor tunicamycin, which causes protein misfolding in the en-
doplasmic reticulum, resulted in more pronounced changes in pro-
teostasis gene mRNAs when given at a nonlethal dose (Fig. 1b and
Supplementary Table 1). However, immunoblotting for ubiquitinated
proteins conﬁrmed that bortezomib and DBeQ perturbed the UPS, with
a clear increase in the level of ubiquitinated proteins in cells treated
with bortezomib, while DBeQ had a minor eﬀect (Fig. 1c and
Supplementary Fig. 3). These observations demonstrate that by ﬁne-
tuning an appropriate dose in diﬀerentiating hMSC, DBeQ and borte-
zomib can impair intracellular proteostasis and trigger mild proteotoxic
stress that is not acutely toxic to cells.
2.2. Neither VCP/p97 nor proteasome inhibition aﬀect gross measures of
hMSC osteogenic diﬀerentiation
Like primary osteoblasts, hMSC form bone-like mineralised nodules
in vitro in response to chemical induction. To study the eﬀects of VCP/
p97 and proteasome inhibition on this process, we ﬁrst used
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conventional Alizarin Red S staining (Fig. 1d and Supplementary
Table 2) and colorimetric calcium content quantitation (Fig. 1e and
Supplementary Table 3), and although subtle qualitative changes in
staining patterns were sometimes evident, we found that neither DBeQ
nor bortezomib treatment resulted in signiﬁcant gross changes in the
formation of mineralised nodules. We also quantiﬁed the expression of
genes associated with osteogenic diﬀerentiation and found that mRNA
levels of RUNX2, ALPL, BSP, and ON were not signiﬁcantly aﬀected by
treatment with DBeQ or bortezomib (Fig. 1f, Supplementary Table 4
and Supplementary Fig. 4). Taken together, these data suggest that mild
Fig. 1. Mild proteostasis perturbations do not grossly aﬀect the osteogenic diﬀerentiation of hMSC. a, Normalised viability of hMSC undergoing osteogenic
diﬀerentiation treated on days 0, 7, 14, and 21 with the indicated concentrations of DBeQ or bortezomib for 48 h (n=3). b, Heatmaps showing relative mRNA
expression levels (normalised to undiﬀerentiated controls) for GADD34, CHOP, BIP, ATF4, VCP, P58IPK, TXNIP and TCF11 in diﬀerentiating hMSC on days 0, 7, 14,
and 21 after treatment for 24 h with DBeQ (5 μM), bortezomib (20 nM), or tunicamycin (5 μg/mL). c, Immunoblotting for β-tubulin and ubiquitinated proteins on
whole cell extracts from undiﬀerentiated hMSC untreated (control) or treated for 4 h or 24 h with 5 μM DBeQ, 20 nM bortezomib, or 5 μg/mL tunicamycin. d,
Quantiﬁcation and representative micrographs showing Alizarin Red S staining (Scale bar= 200 μm) and e, colorimetric calcium content quantitation of diﬀer-
entiated hMSC cultures. f, Relative mRNA expression levels for markers of osteogenic diﬀerentiation compared to undiﬀerentiated controls, which are set to 1 (dotted
horizontal line). In a, d-f, plots show mean + SEM and in b, heat maps show mean of log 2 fold changes in gene expression (normalised to undiﬀerentiated controls)
for hMSC from 3 diﬀerent donors. In d-f, a Kruskal-Wallis non-parametric test followed by Dunn's Multiple Comparison test was used to detect statistical signiﬁcance,
*p < 0.05, **p < 0.01 and ***p < 0.001. For detailed n and p values see Supplementary Tables 1-4. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the Web version of this article.)
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VCP/p97 or proteasome inhibition did not grossly aﬀect the formation
of bone-like mineralised nodules nor the expression of genes known to
be key drivers of osteogenic diﬀerentiation in vitro.
2.3. Proteasome, but not VCP/p97 inhibition, subtly promotes mineralised
matrix formation
Simple, gross observations of osteogenesis are qualitative and can
fail to take into account more subtle aspects of bone formation and
structure [50]. Therefore, to generate quantitative measures of the ef-
fects of proteostasis imbalances on tissue function, we next applied
materials characterisation techniques to analyse the impact of VCP/p97
and proteasome inhibition on diﬀerentiating hMSC's ability to form a
bone-like material in vitro. Raman spectroscopy detects vibrational
chemical bonds, capturing the ‘biochemical signature’ of a substance.
Raman spectroscopy has been used to characterise both the composi-
tion of native ECM [51] and that secreted by cultured cells [50,52,53].
Raman spectra collected from mineralised nodules formed under all
conditions revealed a sharp peak at ∼960 cm−1 indicative of mineral
phosphate ion vibrations (PO43− ν1) and other spectral features typical
of native bone (Fig. 2a) [54]. This observation conﬁrmed that all groups
broadly formed a bone-like material, as previously described
[50,52,53]. We then examined the integrated area of the PO43− ν1
peak, a relative measure of the amount of bone-like apatite [51]. Using
standard univariate peak analysis, we observed an increase (although
not statistically signiﬁcant, p=0.085) in the ν1 PO43− peak area in
bortezomib-treated cultures compared to controls (Fig. 2c and
Supplementary Table 5). VCP/p97 inhibition, on the other hand, did
not alter the intensity of the PO43− ν1 peak. This suggests that whilst
VCP/p97 inhibition did not aﬀect the amount of mineral produced by
hMSC, proteasome inhibition subtly enhanced it, a ﬁnding compatible
with reports of the anabolic eﬀects of proteasome inhibitors on bone
[39,55–57], particularly in multiple myeloma [58–60].
2.4. VCP/p97, but not proteasome inhibition, impacts spectroscopic
measures of mineral crystallinity and decreases proteinaceous matrix
deposition
Raman spectral analyses not only provide information about the
relative quantity of a substance, but also its structure. Therefore, we
next analysed PO43− ν1 peak position as an indicator of mineral crys-
tallinity. A downward shift is associated with a more amorphous, dis-
organised apatite whereas an upward shift suggests that the mineral is
more crystalline [51]. Mean ν1 PO43− peak position for bortezomib-
treated hMSC was similar to that of controls. However, in the DBeQ-
treated group, it was signiﬁcantly higher (Fig. 2d and Supplementary
Table 5). A shift in PO43− ν1 peak position was also evident in diﬀer-
ence spectra generated by comparing mean DBeQ- and bortezomib-
treated conditions to controls (Fig. 2a, bottom-most spectra)). The
‘control-DBeQ’ spectrum produced a shift at ∼960 cm−1, whilst no
shift was evident in the ‘control-bortezomib’ diﬀerence spectrum.
As VCP/p97 inhibition appeared to impact nodules’ mineral crys-
tallinity, we next asked if the proteinaceous component had also been
aﬀected. The Raman peak centred at ∼1660 cm−1 has been attributed
to Amide I and is an indication of protein content [51]. Bortezomib
treatment did not aﬀect the integrated area of the Amide I peak,
however, it was signiﬁcantly lower in DBeQ-treated nodules compared
to controls (Fig. 2e and Supplementary Table 5), suggesting that VCP/
Fig. 2. VCP/p97 inhibition alters mineralised nodule composition as determined by Raman spectroscopy. a, Mean Raman spectra collected from mineralised
nodules formed in control, DBeQ- and bortezomib-treated hMSC cultures. Diﬀerence spectra of DBeQ- and bortezomib-treated cultures compared to controls are
shown in the bottom of the panel. Spectra are oﬀset on the y-axis for clarity. b, Table showing the fraction of spectra in DBeQ- and bortezomib-treated groups and the
control that could be classiﬁed by sensitivity, speciﬁcity and classiﬁcation error using a cross-validated 6-component Partial Least Squares-Discriminant Analysis
model. c, Univariate analyses of the mean PO43− ν1 peak area at∼960 cm−1 in control, DBeQ- and bortezomib-treated cultures, d, mean PO43− ν1 peak position, and
e, 1660 cm−1 peak area. f, Mean mineral to matrix ratio in control, DBeQ- and bortezomib-treated cultures. In c,-f, data are means + SD and a Kruskal-Wallis non-
parametric test followed by Dunn's Multiple Comparison test was used to detect statistical signiﬁcance. *p < 0.05, **p < 0.01 and ***p < 0.001. For detailed n
and p values see Supplementary Table 5.
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p97 inhibition decreased the amount of Amide I-containing protein
secreted by hMSC. This was reﬂected in mineral to matrix ratio, a
measure of the relative amount of apatite to protein in nodules. Whilst
bortezomib-treated nodules were no diﬀerent, DBeQ treatment pro-
duced nodules with signiﬁcantly higher mineral to matrix ratios com-
pared to controls (Fig. 2f and Supplementary Table 5).
We next aimed to conﬁrm the Raman spectroscopic distinctiveness
of nodules formed when hMSC were subjected to VCP/p97 as opposed
to proteasome inhibition by multi-variate analysis techniques. Using a
6-component Partial Least Squares-Discriminant Analysis model, we
found that whilst all groups showed similar classiﬁcation error, we were
able to classify a larger fraction of DBeQ-treated spectra with better
sensitivity and speciﬁcity than either control or bortezomib-treated
groups (Fig. 2b). This suggests that whilst control and bortezomib-
treated mineralised nodules were similar spectroscopically, DBeQ
treatment produced spectra that were more unique and so amenable to
classiﬁcation in the model. Taken together, these observations suggest
not only that VCP/p97 inhibition aﬀected the composition of the cell-
derived mineralised material created by diﬀerentiating hMSC, but also
highlights that these eﬀects were quantiﬁable using a relatively simple
interdisciplinary technique.
2.5. VCP/p97, but not proteasome inhibition, decreases mineralised nodule
stiﬀness
As VCP/p97 inhibition aﬀected the biochemical composition of
mineralised nodules, we next aimed to expand our in vitro model and
determine its eﬀect on nodules' nano-scale mechanical properties by
measuring their stiﬀness. AFM is known for its high-resolution imaging
capabilities; however, it is also a powerful tool for carrying out force-
indentation measurements (Fig. 3a/b), producing quantitative insight
into the mechanical properties of a material at the nano-scale [61]. We
found that Young's modulus (E) was signiﬁcantly lower in nodules
treated with DBeQ compared to controls or those treated with borte-
zomib (Fig. 3c and Supplementary Table 6). As indentation was carried
out with a probe whose tip radius was 8 nm (manufacturer's speciﬁca-
tion), this observation suggests that VCP/p97 inhibition signiﬁcantly
reduced the stiﬀness of the cell-derived material created by diﬀer-
entiating hMSC at the scale of the nano-composite structure of native
bone.
2.6. Proteasome inhibition reduces the strength of adhesion interactions, but
VCP/p97 inhibition enhances the total energy dissipated
In addition to probing their stiﬀness, AFM-based indentation mea-
surements also reveal information regarding the cell-derived materials’
proteinaceous content. This is because upon indentation, the AFM
probe forms non-speciﬁc adhesion interactions with the surface of the
nodule (likely with proteins). During unloading of the indentation
measurement, the deﬂection of the cantilever can reveal the strength of
the adhesion interactions between the probe and the sample, as well as
measure the distance over which those adhesion interactions take place.
We ﬁrst found that adhesion force (Fig. 3d, Supplementary Fig. 5, and
Supplementary Table 6) was not diﬀerent in DBeQ-treated samples
compared to controls; however, in bortezomib-treated samples, it was
signiﬁcantly lower. This suggests that bortezomib-treated nodules in-
teracted with the AFM probe less strongly, likely because the protein
composition was diﬀerent and/or was tightly bound to the more highly
mineralised nodules and thus less available to interact with the AFM
probe.
We next examined the length of the adhesion interactions, a mea-
sure of the distance over which adhesion interactions take place be-
tween the sample and the AFM probe during the unloading phase
(Fig. 3e and Supplementary Table 6). DBeQ treatment produced inter-
actions at signiﬁcantly larger adhesion interactions lengths than those
observed in either control or bortezomib-treated nodules. Analyses of
the distributions showed that in DBeQ-treated nodules, interactions
often took place as the probe retracted several microns from the contact
point (2–4 μm), as conﬁrmed by statistical analyses for trend (Fig. 3e
and Supplementary Table 6). This contrasts with measurements on
control and bortezomib-treated cultures, where most interactions took
place within a few hundred nanometers of the contact point. This was
also evident in measurements of total adhesion energy, which accounts
for both adhesion strength and the distance over which it acts (Fig. 3f
and Supplementary Table 6). All groups showed interactions with the
probe at low values for total energy (ﬁrst peak in histograms at <
20 fJ), likely reﬂecting interactions between the AFM probe and pro-
tein that was strongly bound to mineral. However, median adhesion
energy was signiﬁcantly higher in DBeQ-treated groups and was con-
comitant with many individual measurements at high values of energy
dissipation. These observations suggest that VCP/p97 inhibition pro-
duced nodules that were highly compliant mechanically and whose
protein may have been less tightly bound to the mineral (or the protein
had diﬀerent charge/adhesive properties), and thus could be extended
away from the nodules and dissipate energy via interactions with the
AFM probe. On the other hand, protein in control and bortezomib-
treated nodules may have been more strongly bound to mineral, as in
native bone. Moreover, these observations demonstrate that AFM, a
widely-available technique, can identify quantiﬁable changes in tissue
properties in response to mild VCP/p97 impairment.
2.7. VCP/p97, but not proteasome inhibition impacts the ultra- and micro-
structure of mineralised nodules
As VCP/p97 inhibition aﬀected the biochemical composition, as
well as the mechanical and adhesive properties of the bone-like mate-
rial formed by hMSC, we next aimed to visualise its eﬀects on this
matrix using a combination of transmission (TEM) and scanning elec-
tron microscopy (SEM). TEM micrographs of control and bortezomib-
treated cultures had similar ultrastructures to those previously de-
scribed for bone-like nodules [50,62], and were notable for aligned
ﬁbrous protein between cells (Fig. 4). However, in DBeQ-treated cul-
tures, we often observed more disorganised matrix in the intercellular
space, and aligned ﬁbrous protein was less common. We also examined
nodules by SEM using both backscatter and secondary electron modes.
Combining the two to create density-dependent colour SEM (DDC-SEM)
images allowed us to visualise dense mineralised and less dense pro-
teinaceous areas [63]. hMSC cultured under basal conditions did not
form mineralised nodules (Supplementary Fig. 6). Images of the ma-
terial formed under control conditions and those treated with borte-
zomib contained dense, mineralised areas that appeared to closely as-
sociate with less dense matrix, with morphologies similar to those
previously described [64]. However, in DBeQ-treated cultures, al-
though some dense material localised with matrix, we also observed
highly dense areas with little to no associated less dense matrix.
Moreover, the structure of the dense mineral in DBeQ-treated cultures
appeared diﬀerent morphologically. Whilst dense mineralised areas of
control cultures appeared smooth, mineral in DBeQ-treated cultures
appeared rougher, with needle-like crystals characteristic of non-phy-
siological precipitation (Supplementary Fig. 7).
3. Discussion
Here, we used a combination of materials science-based character-
isation approaches to show that very mild impairment of intracellular
proteostasis can modify tissue physical properties in a cell-derived in
vitro model that mimics the formation of native bone tissue. Alizarin
Red S staining and calcium quantiﬁcation showed that DBeQ- and
bortezomib-treated as well as control cultures all produced a similar
amount of mineralised material. However, by quantifying the PO43− ν1
peak intensity of Raman spectra, we determined that bortezomib-
treated samples produced numerically (but not statistically signiﬁcant)
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more apatite than other groups. Alizarin red S staining is a crude esti-
mate of bone formation and whilst it detects the presence of calcium-
containing compounds [41], bone mineral is more complex. Here,
Raman spectral measurements were able to provide more speciﬁc in-
formation regarding bone-like tissue formation.
In our in vitro model, Raman spectroscopy identiﬁed quantitative
eﬀects of VCP/p97 inhibition, which contrasted with those of protea-
some inhibition. Speciﬁcally, whilst DBeQ appeared to increase mineral
crystallinity, bortezomib had no signiﬁcant eﬀect on spectroscopic
measures of apatite structure. Mineral crystallinity increases with age
[35] and has been associated with decreased bone ductility [36] and
increased fracture risk [65], suggesting spectroscopic measurements
may provide informative functional measurements of bone quality.
VCP/p97 inhibition also signiﬁcantly decreased nodule protein content,
producing a higher mineral to matrix ratio when compared to controls.
Although bortezomib treatment subtly promoted mineral formation,
this was accompanied by appropriate formation of proteinaceous ma-
trix, as mineral to matrix ratio was not diﬀerent than that of controls.
As bone formation is a highly controlled process in which mineral
templates on a proteinaceous matrix, this observation suggests that
whilst bortezomib increased mineralisation (in line with previous ob-
servations [39,57,58]), proteasome inhibition did not fundamentally
interfere with this process. DBeQ treatment, on the other hand, induced
the formation of mineral in the absence of appropriate proteinaceous
matrix deposition, suggesting that the mineral may have been aberrant.
As Raman spectral measurements are relatively straightforward and can
be performed on almost any biological sample under any condition
(wet/dry/ﬁxed/unﬁxed/etc.) in the absence of labelling or staining,
these observations highlight the technique's utility as a quantitative
means to identify functional tissue eﬀects of VCP/p97 perturbations.
One of bone's primary roles is to resist applied load. Therefore, its
mechanical properties, including stiﬀness, are central to its function.
Indeed, pathological changes in mechanical properties are associated
with diseases including osteogenesis imperfecta, osteopetrosis, osteo-
porosis and rickets [66]. Our AFM-based indentation measurements
showed that whilst bortezomib had no eﬀect on the cell-derived ma-
terials' stiﬀness, DBeQ signiﬁcantly decreased their Young's modulus.
Diﬀerences in stiﬀness are likely not attributable to cultures forming
less mineral, as both histochemical staining and spectroscopic analyses
showed that VCP/p97 inhibition did not reduce the amount of mineral
compared to control cultures. Instead, our observations suggest that
DBeQ altered either the composition or structure of mineralised no-
dules. In bone, the protein-mineral nano-composite provides toughness
via pre-stress within its structure. This is mediated by cross-linked
collagen ﬁbres, which impart compressive stress on mineral crystals as
they form, whilst the growing mineral crystals tense the collagen
structure [67]. Our observations that DBeQ-treated nodules were less
stiﬀ suggests that these composite interactions may have been limited.
Our AFM-based indentation measurements also produced highly
informative observations with regards to adhesion interactions.
Adhesion interactions with the AFM probe can be mediated by non-
speciﬁc interactions, likely with protein via hydrophobic, ionic, steric,
and/or Van der Waals forces [68]. We observed that DBeQ, but not
bortezomib treatment, led to striking changes in key measures of ad-
hesion, including energy dissipation, suggesting that protein within
DBeQ-treated nodules was either less tightly bound to mineral or the
proteome of DBeQ-treated nodules diﬀered from that in control or
bortezomib-treated groups. Bone mineralisation is thought to occur
when negatively charged proteins stabilise disordered mineral pre-
cursors, which later become more crystalline and grow [69], creating a
nano-composite structure. This structure requires a precise protein
composition to allow for correct formation. Our observations suggest
that in DBeQ-treated cultures, this balance may have been disrupted,
precluding the formation of bone-like mineral with appropriate
Fig. 3. Proteasome and VCP/p97 inhibition have diﬀering eﬀects on mineralised nodules' stiﬀness and adhesion interactions. a, Schematic showing how
mineralised nodules were probed by AFM in force-indentation mode using a cantilever with a pyramidal tip. b, Typical force-indentation curve generated from
indenting a mineralised nodule. Schematic shows how nodule stiﬀness and adhesion interactions were calculated from the retraction curve. c, Measurements of
Young's Modulus (Pa) of mineralised nodules. Plots show medians, 1st and 3rd quartiles and highest and lowest values. d, Measurements of adhesion force, e, length
of adhesion interactions and f, adhesion energy generated from force-indentation curves on control, DBeQ- and bortezomib-treated cultures. Plots show medians.
Histograms with their associated statistical analyses show how the distributions of values diﬀered between the groups. In c.-f. a non-parametric Kruskal-Wallis test
followed by Dunn's multiple comparison was used to determine statistical signiﬁcance. Signiﬁcant diﬀerences in the distributions of adhesion values were evaluated
using a Mantel-Haenszel linear-by-linear association Chi-squared (χ2) test for trend. Power was evaluated by determining Goodman and Kruskal's gamma (γ).
*p < 0.05, **p < 0.01 and ***p < 0.001. For detailed n and p values see Supplementary Table 6.
Fig. 4. VCP/p97 inhibition impacts the
ultra- and micro-structure of mineralised
nodules. Transmission electron microscopy
(TEM) and density-dependent colour scan-
ning electron microscopy (DDC-SEM) mi-
crographs of mineralised nodules formed
from hMSC under standard osteogenic con-
ditions or treated with DBeQ or bortezomib.
In TEM images, proteinaceous ﬁbrils are
evident in the intercellular space in control
and bortezomib-treated cultures. In DBeQ-
treated samples, the proteinaceous matrix
between cells appeared amorphous and
clear ﬁbrils were often not evident. Scale
bar= 250 nm. In DDC-SEM micrographs,
images were coloured in post-processing by
combining images from secondary and
backscatter electron detectors to identify
dense mineral (red) and less dense matrix
(green). In control and bortezomib-treated
groups, there appears to be an association
between the organic matrix and the mi-
neral. In DBeQ-treated groups, dense mineral was often detected without the associated presence of less-dense matrix. Images are representative from experiments
carried out on cultures grown from 3 independent donors. Scale bar= 2 μm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the Web version of this article.)
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nanostructure. However, despite our quantitative insights, the eﬀects of
mild VCP/p97 impairment were subtle and not all adhesion interactions
in DBeQ-treated groups displayed long-range, energy dissipative be-
haviours. Indeed, distributions revealed many measurements with
short-range behaviour, similar to that in control and bortezomib-treated
groups. Indeed, our observations suggest that either a subset of cells
secreted protein that produced aberrant interactions, or a subset of the
secreted proteome was aberrant.
TEM and SEM imaging suggested that DBeQ diﬀerentially aﬀected
the ultra- and micro-structure of the bone-like material created by
hMSC compared to bortezomib treatment. Indeed, in DBeQ-treated
samples, we observed amorphous rather than ﬁbrillar proteinaceous
matrix in the intercellular spaces. As apatite templates on ﬁbrillar
collagen in native bone, this observation lends further support to our
AFM-based ﬁndings that mineral failed to strongly interact with ap-
propriate protein to create a bone-like nano-structure. DDC-SEM images
similarly suggested a lack of close association between less dense matrix
and denser mineral in DBeQ-treated cultures. Moreover, high magniﬁ-
cation secondary electron SEM images of DBeQ-treated cultures re-
vealed needle-like mineral, akin to that observed in non-physiological
precipitation reactions [70]. These observations suggest that in addition
to an aberrant cell-mediated mineralisation process, the more crystal-
line mineral in DBeQ-treated cultures could have been formed in a pure
physicochemical process, similar to that in pathological calciﬁcations
[63].
Here, we describe a cell-derived, biomaterial-based in vitro model of
bone formation whereby we used pharmacological inhibition of two
key components of the intracellular protein degradation apparatus to
induce mild cellular stress. We then identiﬁed a series of relatively
straightforward, widely available techniques from materials science
that allowed us to quantitatively characterise changes to tissue bio-
chemical composition, mechanical and adhesive properties, as well as
observe morphological changes to their micro- and ultra-structure. This
combination of materials science characterisation techniques is parti-
cularly amenable for analysing changes in bone-like tissue formation
because neither AFM-based indentation, Raman spectroscopy nor the
imaging techniques requires speciﬁc staining/labelling, which would
require a priori knowledge of speciﬁc targets of the inhibition. The
limitation of this approach, of course, is that speciﬁc targets are not
identiﬁed; however, as VCP/p97 and the proteasome inhibitors aﬀect
the proteome broadly, this approach may be superior. Moreover, as the
techniques analyse the physical material created by cells, they can also
detect potential post-translational changes in proteins, which may im-
pact on cell/tissue function. These changes may be missed by standard
proteomic techniques, for example. In time, techniques such as single
cell proteomics that can analyse post-translation modiﬁcations to pro-
teins may become widely available; however, until then, physical sci-
ence-based characterisations may remain the gold standard.
As our in vitro experimental platform allows for the functional ef-
fects of proteostasis imbalances to be evaluated quantitatively, it may
ﬁnd use in high-throughput pre-clinical drug screening purposes [71],
particularly to evaluate the functional eﬀects on tissues of therapies
designed to treat diseases stemming from perturbed proteostasis or for
cancer therapies targeting protein degradation. Given that multiple
components of protein degradation pathways are being investigated as
anti-cancer drug targets, our ﬁndings both highlight potential un-
wanted skeletal eﬀects such approaches might bring, and also oﬀer an
early preclinical screening tool. Finally, cell-derived, ECM-based bio-
materials akin to the mineralised nodules formed by our hMSC cultures
are highly promising as potential scaﬀolds for tissue engineering
[41,42]. As these materials are secreted/arranged by tissue-speciﬁc
cells, they are both composed of appropriate ECM and contain tethered
growth and other regulatory factors to direct seeded SC. However,
tissue engineering approaches such as culture on 3D scaﬀolds can ex-
pose cells to reactive oxygen species, acidosis and hypoxia, all of which
are known to perturb proteostasis and activate the unfolded protein
response [72]. Our ﬁnding that mildly perturbing proteostasis sig-
niﬁcantly impacts tissue properties suggests that maintaining proteos-
tasis may be essential in forming ECM-based biomaterial scaﬀolds that
replicate the native tissue.
4. Conclusions
Using a cell-derived model of bone formation in which we mildly
perturb proteostasis, we have shown that a combination of techniques
from materials science can quantitatively detect tissue eﬀects that may
explain some of the pathologies associated with VCP/p97-related dis-
eases. This model may have important implications for studying VCP/
p97-related diseases. This is because there are no existing in vivomodels
that can replicate the subtle/intermittent proteostasis imbalances that
characterise these diseases. Moreover, this is the ﬁrst in vitro model we
are aware of that examines the eﬀects of proteostasis imbalances on the
mechanical, morphological and biochemical characteristics of tissues,
as previous in vitro studies using pharmacological agents to perturb
proteostasis have only carried out limited molecular analyses, which
provide little insight into the tissue pathologies observed in patients.
Furthermore, whilst Raman spectroscopy, AFM and electron micro-
scopy have been used to analyse tissues [51,63], including the material
formed by cells in vitro [50,52,53]; to our knowledge this is the ﬁrst
report using these techniques to analyse tissue changes mediated by
VCP/p97 and/or proteasome inhibition.
5. Methods
5.1. hMSC expansion
Human samples used in this research project were obtained from the
Imperial College Healthcare Tissue Bank (ICHTB, HTA license 12275).
ICHTB is supported by the National Institute for Health Research
Biomedical Research Centre based at Imperial College Healthcare NHS
Trust and Imperial College London. ICHTB is approved by the UK
National Research Ethics Service to release human material for research
(12/WA/0196), and the samples for this project were issued from sub-
collection R16052. Bone marrow aspirates were obtained at St. Mary's
Hospital Imperial College Healthcare NHS Trust (IHCNT) from healthy
paediatric stem cell donors. hMSC were expanded for clinical use for
the treatment of Graft-versus-Host-Disease. Written informed consent
for the use of hMSC for research was obtained from the donors' parents.
Primary cultures were established using CellSTACK® culture cham-
bers, ﬁlling caps (Corning Incorporated, Life Sciences) and
Macopharma seeding sets (Macopharma) with a grade A cleanroom
environment under good manufacturing practice (GMP) conditions. We
targeted a seed rate of 25×106 total nucleated cells per level. Cells
were cultured in Minimum Essential Medium α with GlutaMAX™
(αMEM, Gibco) supplemented with 5% in-house made platelet lysate.
Platelets obtained by apheresis from 10 donors by the National Blood
Service were pooled, centrifuged at 3000 rpm for 10min to eliminate
platelet bodies, and frozen at −80 °C. Platelet lysate pools were batch-
tested for their ability to support hMSC growth. Cells were cultured in a
humidiﬁed incubator in 5% CO2 at 37 °C until conﬂuent. When con-
ﬂuent (usually after 14 days) cells were harvested and cryopreserved
using a controlled rate freezer in 5% human albumin solution (Biotest)
containing 10% DMSO (CryoPur™, OriGen) in a 1:1 ratio. Prior to
cryopreservation, hMSC were immunophenotyped by staining with a
panel of labelled mouse anti-human antibodies (CD105-APC, CD73-PE,
CD90-APC, CD45-FITC, CD34-PE, CD3−, CD19-PE, HLA-DR-FITC and
CD14-PE; BD Biosciences) using a FACSCalibur™ analyser (BD
Biosciences) and CELLQUEST software. hMSC expressed CD90, CD105,
and CD73 and were negative for hematopoietic markers CD34 and
CD45 [73] (data not shown).
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5.2. Cellular metabolic activity
Cellular metabolic activity as a read-out of cellular viability was
measured using the Alamar Blue® (Life Technologies) assay according to
the manufacturer's instructions. The assay is based on the reduction of
resazurin, a non-ﬂuorescent dye, to highly ﬂuorescent red resoruﬁn in
healthy cells. The Alamar Blue® cell viability reagent was incubated at
10% of sample volume for 1–4 h at 37 °C, and the ﬂuorescence (590 nm)
of the sample measured using a FLUOstar Omega BMG Labtech plate
reader. Viability was determined relative to untreated cells or cells
treated with vehicle only.
5.3. Osteogenic diﬀerentiation of hMSC and inhibitors
hMSC were seeded at 5×103 cells/cm2 in α-MEM. After 24 h, cells
were approximately 80% conﬂuent and osteogenic diﬀerentiation was
initiated by switching to commercially available Stempro® Osteogenesis
Diﬀerentiation kit medium (Invitrogen) or osteogenic diﬀerentiation
medium consisting of α-MEM, 15% FBS, 100 μM ascorbic acid
(Scientiﬁc Lab Supplies, UK), 2.5mM β-glycerophosphate (Calbiochem)
and 100 nM dexamethasone (Sigma). For experiments on un-
diﬀerentiated hMSC, cells were grown in α-MEM supplemented with
10% heat-inactivated foetal bovine serum (FBS, Sigma), 1000 U/mL
penicillin, and 10mg/mL streptomycin (Sigma). Medium was changed
every 3–4 days, and cells were used until passage 8 only. VCP/p97 and
the proteasome were inhibited with DBeQ (Biovision) or bortezomib
(Calbiochem). Tunicamycin was purchased from Sigma.
5.4. Myeloma cell line
Human OPM-2 multiple myeloma cells (obtained from the Deutsche
Sammlung von Mikroorganismen und Zellkulturen DSMZ; identity
conﬁrmed using short tandem repeat proﬁling of 10 loci (Core Genomic
Facility, Medical School, University of Sheﬃeld)) were cultured in
RPMI-1640 (Invitrogen) supplemented with 10% FBS.
5.5. RNA extraction and reverse transcription
Cells were harvested and snap frozen using liquid nitrogen. RNA
was extracted using the GeneJET RNA Puriﬁcation kit (Thermo
Scientiﬁc) followed by removal of genomic DNA according to the
manufacturer's instructions. Remaining traces of DNA were removed
using DNase I treatment (Invitrogen). cDNA synthesis was performed
using the RevertAid First Strand cDNA Synthesis kit (Thermo Scientiﬁc)
according to the manufacturer's instructions using an Applied
Biosystems 2720 Thermal Cycler (Life Technologies).
5.6. Quantitation of gene expression by real-time PCR
PCR reactions were performed on an Applied Biosystems
StepOnePlus™ PCR machine using 10 μL SYBR Green JumpStart™ Taq
ready Mix™ PCR (Sigma), 0.48 μL sequence-speciﬁc primers at 300 nM
(Supplementary Table 7) and 5 μL cDNA. A three-step cycle was em-
ployed: (1) denaturation at 94 °C for 2min; (2) annealing/extension at
60 °C for 1min; and (3) melting from 60 °C to 94 °C for 2.5min. The
ΔΔCT method was used to quantify fold changes in expression (2−ΔΔCq)
of each gene of interest and normalised to the expression of GAPDH in
undiﬀerentiated control cells.
5.7. Immunobloting
Whole-cell protein extracts were prepared on ice using a lysis buﬀer
(Cell Signalling) supplemented with Complete EDTA-free Protease
Inhibitor Cocktail (Roche). Then, after 10min on ice and centrifugation
at 4 °C (14,000 rpm) for 10min, the supernatant was collected. Protein
concentration was measured using Bradford reagent (Bio-RAD)
according to the manufacturer's instructions. Proteins were denatured
at 100 °C for 5min with standard SDS-PAGE Loading Buﬀer (200mM
Tris-Cl, pH 6.8), 400mM DTT, 8% SDS, 0.4% bromophenol blue, 40%
glycerol). Proteins were separated on a 10% SDS polyacrylamide gel
using electrophoresis and transferred to PVDF membranes (GE
Healthcare). Membranes were blocked with 0.1% TBST (Tris-Buﬀered
Saline, Tween20) containing 5% non-fat milk for 1 h at room tem-
perature, incubated with primary antibodies against ubiquitin (Cell
Signalling Technology, cat. no. 39335) and beta-tubulin (Cell Signalling
Technology, cat. no. 21465) and then with a secondary anti-rabbit IgG
labelled with horseradish peroxidase (Cell Signalling Technology, cat.
no. 70745). Finally, an electrochemiluminescence (ECL ™ Western
Blotting Reagents, GE Healthcare) system was used to detect proteins.
5.8. Alizarin Red S staining
Mineralisation was measured by staining with Alizarin Red S (ARS),
a Ca2+-binding dye. Cells were washed with phosphate-buﬀered saline
(PBS; Sigma) and ﬁxed in 10% formalin in PBS for 20min. Cells were
washed twice in PBS followed by staining with 2% (w/v) Alizarin Red S
(Sigma) solution in dH2O (after adjusting the pH to 4.2 using 10%
NH4OH) for 10min at room temperature. The dye solution was drained
and the cells washed with running water for 30min. Cultures were
visualised using an EVOS ×1 Core digital inverted cell imaging mi-
croscope system.
5.9. Calcium quantiﬁcation
Diﬀerentiated cell cultures were rinsed with PBS and then incubated
at 4 °C on an orbital shaker overnight in 0.5 M HCl. Calcium quantiﬁ-
cation was then performed on lysates using the Calcium Colorimetric
Assay kit (BioVision) according to the manufacturer's instructions.
Brieﬂy, 10 μL of sample (HCl with dissolved nodules) or known stan-
dards were incubated with 90 μL of chromogenic reagent that binds to
the complex formed between calcium ions and 0-cresolphthalein, and
60 μL of assay buﬀer. The absorbance was then measured at 575 nm
using a FLUOstar Omega BMG Labtech plate reader. The calcium con-
centration in the samples was then calculated using a standard curve
generated using serial dilutions (0–2 μg).
5.10. Raman spectroscopy measurements and analyses
For Raman spectroscopy measurements, hMSC were cultured as
described above, but were seeded on MgF2 coverslips (Crystran, UK)
instead of tissue culture plastic to facilitate Raman spectral analyses.
MgF2 is a weak Raman scatterer, whilst tissue culture plastic produces
an intense Raman signal [74]. After 21 days in culture, MgF2 coverslips
were brieﬂy rinsed with deionised H20 and dried in a bell jar desiccator
[50]. Raman measurements were performed using a custom build
Raman system consisting of a Laser Quantum Ventus 532 nm Laser
(Stockport, UK). The laser was coupled via free space optics into an
Olympus BX60 microscope (Hamburg, DE). Raman scattered light was
collected through a 50×/NA 0.8 objective and ﬁbre coupled into an
Acton SpectraPro 2500i f/6.5 spectrograph, using a 1200 lines/mm
grating with a Princeton Instruments PIXIS 400F 1340×400 pixel CCD
camera (Trenton, NJ) operating at −75 °C. Integration time was 10 s,
averaged 3 times for each spectrum, using 30mWat the sample. We
have previously shown that these conditions do not cause spectral
changes due to sample heating/burning [52]. For univariate peak
analyses, between 295 and 315 spectra were examined per group.
Data were smoothed using a 5 point Savitzky-Golay ﬁlter and
background corrected by a 5th order polynomial using an automated
weighted least squares ﬁtting method [75]. To determine the position
of the PO43− ν1 peak at ∼960 cm−1, a single Gaussian was ﬁt to the
data, as previously described [76,77]. Gaussian ﬁts were used to cal-
culate the 960 cm−1 (PO43− ν1) and 1660 cm−1 (Amide I) peak areas.
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The mineral to matrix ratio was calculated by determining the ratio of
the area of the 960 cm−1 peak to that of the 1660 cm−1 peak [50,51]
after normalization using Multiplicative Scatter Correction. Spectra
with a PO43− ν1 peak area of less than 500 were excluded from mul-
tivariate analyses and in total, spectra collected from 29 control-, 38
DBeQ- and 42 bortezomib-treated cultures were analysed. For classiﬁ-
cation analyses, a 6-component Partial Least Squares-Discriminant
Analysis model was ﬁtted and cross validated using venetian blinds and
10 splits.
5.11. Atomic force microscopy (AFM) measurements of nodule stiﬀness and
adhesion
22mm glass coverslips were prepared by soaking in FBS overnight
and allowing to air dry. hMSC were seeded at 190,000 cells/coverslip.
The next day, basal medium was replaced with osteogenic medium and
cells were diﬀerentiated as described above. After 21 days, coverslips
were frozen slowly [50]. Brieﬂy, medium was aspirated from plates and
replaced with a 1:1 solution of 20% DMSO in FBS:basal medium. Plates
were then sealed with paraﬁlm and placed within 2 nesting polystyrene
boxes at −80 °C. Samples were defrosted at room temperature im-
mediately prior to measurements. Coverslips were immobilised on
60mm diameter tissue culture dishes (TPP, CH) by gluing small cov-
erslips to the plate at the sample edges. Coverslips were immersed in
PBS (without calcium and magnesium, pH 7.4, Gibco) and measure-
ments were made at room temperature. Mineralised nodules were
identiﬁed from bright ﬁeld images as dense, opaque patches on the
culture surface that varied in diameter between ∼35 and 125 μm. In-
dentation measurements were carried out on a JPK Nanowizard® I AFM
equipped with a cantilever (cantilever B, spring constant, K ∼16 N/m)
with a pyramidal, silicon AFM probe (HQ:NSC35/Hard/AL BS, Mikro-
Masch®, DE). Cantilevers were calibrated using the thermal method
[78]. Analysis was performed using J Unicam and JPK SPM software
2.3 01/2006 (JPK Instruments AG, DE). Indentations were carried out
at 1 Hz under a constant loading rate with a relative setpoint force set as
3650 nN and no dwelling time. The eﬀect of the hard underlying sub-
strate was assumed to be negligible as the indenter penetration was less
than 10% of the nodule thickness [79,80]. Nanoindentations were
made at between 1 and 5 locations on each nodule's surface. 20 in-
dividual force indentation curves were made at each location
(1× 1 μm2). Measurements were performed on at least 12 nodules per
donor per treatment. Young's modulus (E), maximum adhesion force,
maximum length of adhesion interactions, and adhesion energy were
determined in JPK SPM software using the Hertz model. The Poisson's
ratio of both the sample and tip were assumed to be 0.3 [81].
5.12. Transmission electron microscope (TEM) imaging
Diﬀerentiated hMSC cultures were scraped from plates and pelleted
in PBS. Pellets were ﬁxed with 1% (w/v) glutaraldehyde for 15min,
then washed in cacodylate buﬀer three times, followed by incubation in
1% (w/v) osmium tetroxide and 1.5% (w/v) potassium ferrocyanide in
H2O for 1 h. Pellets were then washed in H2O three times and dehy-
drated in an ethanol/distilled water series at concentrations from 20 to
100% ethanol for 15min in each. Samples were then inﬁltrated with
Epon 812 (EMS) epoxy resin in absolute ethanol at ratios of 3:1, 2:1,
1:1, 1:2, 1:3 (ethanol:resin) and then 100% epoxy resin for 6 h each.
Samples were then cured at 60 °C for 48 h. Resin blocks were sectioned
on a Leica Ultracut EM FC7 ultramicrotome on an ultracut UC7 chassis
into 80 nm sections, placed on grids, stained with Reynold's lead citrate
for 15min and 1% (w/v) uranyl acetate for 15min, then imaged on a
Jeol 1010 TEM at 80 KV.
5.13. Scanning electron microcope (SEM) imaging
Cultures in well plates were dehydrated using increasing
concentrations of ethanol (20%, 30%, 40%, 50%, 60%, 70%, 80%,
90%, 100%, 100% and 100% for 10min each) and mounted on SEM
stubs using carbon tape. Silver painting and carbon coating was carried
out using a Quorum K975X Carbon coater. Samples were imaged on
either a Hitatchi Se3499N or a Zeiss Sigma. For DDC-SEM images,
secondary electron (SE) mode was used to obtain topographic in-
formation, whilst the backscattered electron detector (BSE) was applied
to diﬀerentiate between organic and inorganic material. DDC-SEM
images were produced by assigning diﬀerent colours to the BSE and SE
modes using Image J.
5.14. Statistical analyses
Statistical analyses for all measurements were carried out using a
non-parametric Kruskal-Wallis test followed by Dunn's multiple com-
parison test unless stated otherwise. All analyses were carried out using
GraphPad Prism version 7 for Windows (GraphPad Software, USA).
Signiﬁcant diﬀerences in the distributions of adhesion values between
treatments were evaluated using a Mantel-Haenszel linear-by-linear
association Chi-squared (χ2) test for trend. Power was evaluated by
determining Goodman and Kruskal's gamma (γ) and standardised re-
siduals (SR) were used to identify the most signiﬁcant intervals that
contributed to diﬀerences between histograms, all three using IBM®
SPSS® statistics version V23. p values are indicated in ﬁgure captions,
*p < 0.05, **p < 0.01 and ***p < 0.001 and showed in detail in
supplementary tables.
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